Multi-modal neo-adjuvant anti-obesity medications may be more effective than medically supervised weight loss or GLP-1 therapy alone in preparing body mass index (BMI)≥70 patients for metabolic surgery
Authors' conclusion
mmAOM treatment yields the highest %TBWL, especially within the first 51 weeks of preoperative preparation, demonstrating superior efficacy over Mono-GLP-1 and NP-MSWL in patients with BMI ≥ 70 kg/m². These findings suggest that incorporating mmAOM in preoperative protocols could optimize weight loss and improve surgical outcomes for high BMI patients.
Study context
- Population
- Patients with BMI ≥ 70 kg/m² preparing for metabolic surgery, single metabolic disease treatment institute
- Participants
- 113 patients
- Exposure
- Multi-modal anti-obesity medications (mmAOM) vs Mono-GLP-1 vs non-pharmacologic medically supervised weight loss (NP-MSWL) before metabolic surgery
- NP-MSWLn = 13
- Mono-GLP-1n = 54
- mmAOMn = 46
- Outcome
- Mean percent total body weight loss (%TBWL)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
%TBWL
- Significant differences among groups (Kruskal-Wallis test)
- P = 0.0047
Observational data: associations, not effects.
Secondary outcomes
%TBWL across time intervals (0-23, 23-51, 51-88, 88+ weeks)
- Highest median %TBWL at 51-88 weeks: 10.25 [6.49-16.45]
- P = 0.0093
Original publication
Multi-modal neo-adjuvant anti-obesity medications may be more effective than medically supervised weight loss or GLP-1 therapy alone in preparing BMI≥70 patients for metabolic surgery. Int J Obes (Lond). Published 2 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →